Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study

Clinical Cancer Research

Volumn 6, Issue 12, 2000, Pages 4725-4732

  Van Kesteren, C ^a   Cvitkovic, E ^a   Taamma, A ^a   Lopez Lazaro L ^a   Jimeno, J M ^a   Guzman, C ^a   Mathot R A A ^a   Schellens, J H M ^a   Misset, J L ^a   Brain, E ^a   Hillebrand, M J X ^a   Rosing, H ^a   Beijnen, J H ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TRABECTEDIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; BLOOD TOXICITY; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOCYTE COUNT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ALANINE TRANSAMINASE; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; DIOXOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; ISOQUINOLINES; LIVER; MALE; MIDDLE AGED; MODELS, CHEMICAL; NEOPLASMS; NEUTROPENIA; TETRAHYDROISOQUINOLINES; THROMBOCYTOPENIA; TIME FACTORS;

EID: 0034490073     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Progress in the acquisition of new-marine-derived anticancer compounds: Development of Ecteinascidin-743 (ET-743)
2. Some hope from marine derived natural products
3. Phase II of Didemnin B in central nervous system tumors
4. A Phase II study of bryostatin 1 in metastatic malignant melanoma
5. Phase I trial of dolastatin-10 (NSC 376128) with advanced solid tumors
6. Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies
7. Phase II trial of Didemnin B (DDB) in previously treated non-Hodgkin's lymphoma (NHL): An Eastern Cooperative Oncology Group (ECOG) study (EST 1489)
8. In vitro schedule dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743)
9. In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients
10. Ecteinascidin-743, a new marine natural product with potent antitumour activity on human ovarian carcinoma xenografts
11. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer
12. Analysis of Ecteinascidin 743, a new potent marine derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction
13. Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry
14. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by Ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata
15. NMR-based model of an Ecteinascidin 743-DNA adduct
16. Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove
17. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA
18. Effect of Ecteinascidin 743 (ET-743) on the interaction between transcription factors and DNA
19. The antitumor agent Ecteinascidin 743 (ET743), inhibits transcriptional activation of the MDR1 gene by multiple inducers
20. Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: Ecteinascidin 743, isohomohalichondrin-B and LL-15
21. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove
22. Kinetics of pharmacologic response
23. Final results of a Phase I study of Ecteinascidin-743 (ET-743) 24 hour (h) continuous infusion (CI) in advanced solid tumors (AST) patients (pts.)
24. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring
25. Cytochrome P450 catalyzed metabolism of Ecteinascidin 743 by rat and human liver microsomes
26. Pharmacologically guided Phase I clinical trials based upon preclinical drug development